Tortugas Neuroscience is a clinical-stage, neurology-focused biotech led by CEO Jeff Jonas and based in Framingham, MA. Its pipeline, in-licensed from Eisai Co., Ltd. and Jiangsu Hansoh Pharmaceutical Group Ltd., includes potential treatments for schizophrenia, tinnitus, focal epilepsy, reversible encephalopathies and other CNS indications. Programs center on small-molecule new chemical entities with derisked mechanisms of action designed as once-daily oral formulations with differentiated pharmacological profiles and indication-expansion potential. The company is advancing two lead candidates through Phase 2 clinical trials. The recent $106M Seed and Series A financings are intended to support ongoing research and development and completion of those Phase 2 studies.

Total raised

$106M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2026